Biosimilars and follow-on biologics.
This was the Center for Business Intelligence's 2nd Annual Summit on Biosimilars. The participants included industry, government, academics and private professionals involved in the myriad issues of biosimilars. Its purpose was to present a dialogue to evaluate the legal, regulatory and economic landscape in the USA and abroad and prepare for the anticipated US legislation that will enable the entry of biosimilars. Another conference will be held in September to discuss the various pending biosimilar bills in more detail or the new law, if passed.
Fuhr
Joseph P
JP
Widener University, One University Place, Chester, PA 19013, USA. jpfuhr@widener.edu
D002170:Canada; D016568:Drugs, Generic; D007880:Legislation, Drug / Q000639:trends*; D013810:Therapeutic Equivalency; D014481:United States; D014485:United States Federal Trade Commission; D014486:United States Food and Drug Administration; D014944:World Health Organization
D016568:Drugs, Generic